当前位置: 首页 >> 检索结果
3321. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.
作者: Silvio Danese.;Janusz Rudziński.;Wolfgang Brandt.;Jean-Louis Dupas.;Laurent Peyrin-Biroulet.;Yoram Bouhnik.;Dariusz Kleczkowski.;Peter Uebel.;Milan Lukas.;Mikael Knutsson.;Fredrik Erlandsson.;Mark Berner Hansen.;Satish Keshav.
来源: Gut. 2015年64卷2期243-9页
Interleukin-13 (IL-13) has been implicated as a key driver of UC. This trial evaluates the efficacy and safety of tralokinumab, an IL-13-neutralising antibody, as add-on therapy in adults with moderate-to-severe UC despite standard treatments.
3322. Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms (the SAFE trial): a multicentre prospective randomised controlled non-inferiority trial.
作者: Satoshi Mochizuki.;Noriya Uedo.;Ichiro Oda.;Kazuhiro Kaneko.;Yorimasa Yamamoto.;Takeshi Yamashina.;Haruhisa Suzuki.;Shinya Kodashima.;Tomonori Yano.;Nobutake Yamamichi.;Osamu Goto.;Takeshi Shimamoto.;Mitsuhiro Fujishiro.;Kazuhiko Koike.; .
来源: Gut. 2015年64卷3期397-405页
To clarify the effectiveness of second-look endoscopy (SLE) at preventing bleeding after gastric endoscopic submucosal dissection (ESD).
3323. Interferon gamma receptor 2 gene variants are associated with liver fibrosis in the general population: the Rotterdam Study.
作者: Elisabeth P C Plompen.;Bettina E Hansen.;Jeoffrey N L Schouten.;Sarwa Darwish Murad.;Daan W Loth.;Willem Pieter Brouwer.;Aaron Isaacs.;Pavel Taimr.;Albert Hofman.;Cornelia M van Duijn.;André G Uitterlinden.;Bruno H C Stricker.;Frank W G Leebeek.;Harry L A Janssen.
来源: Gut. 2015年64卷4期692-4页 3325. Bone marrow Th17 TNFα cells induce osteoclast differentiation, and link bone destruction to IBD.
作者: Thomas Ciucci.;Lidia Ibáñez.;Agathe Boucoiran.;Eléonore Birgy-Barelli.;Jérôme Pène.;Grazia Abou-Ezzi.;Nadia Arab.;Matthieu Rouleau.;Xavier Hébuterne.;Hans Yssel.;Claudine Blin-Wakkach.;Abdelilah Wakkach.
来源: Gut. 2015年64卷7期1072-81页
Under both physiological and pathological conditions, bone volume is determined by the rate of bone formation by osteoblasts and bone resorption by osteoclasts. Excessive bone loss is a common complication of human IBD whose mechanisms are not yet completely understood. Despite the role of activated CD4(+) T cells in inflammatory bone loss, the nature of the T cell subsets involved in this process in vivo remains unknown. The aim of the present study was to identify the CD4(+) T cell subsets involved in the process of osteoclastogenesis in vivo, as well as their mechanism of action.
3327. miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD.
作者: Wei Wu.;Chong He.;Changqin Liu.;Anthony T Cao.;Xiaochang Xue.;Heather L Evans-Marin.;Mingming Sun.;Leilei Fang.;Suxia Yao.;Irina V Pinchuk.;Don W Powell.;Zhanju Liu.;Yingzi Cong.
来源: Gut. 2015年64卷11期1755-64页
Although both innate and adaptive responses to microbiota have been implicated in the pathogenesis of IBD, it is still largely unknown how they are regulated during intestinal inflammation. In this report, we investigated the role of microRNA (miR)-10a, a small, non-coding RNA, in the regulation of innate and adaptive responses to microbiota in IBD.
3328. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation.
作者: Joanna A Leithead.;Neil Rajoriya.;Nadeem Tehami.;James Hodson.;Bridget K Gunson.;Dhiraj Tripathi.;James W Ferguson.
来源: Gut. 2015年64卷7期1111-9页
Recent data have suggested that non-selective β-blockers (NSBB) are associated with increased mortality in patients with cirrhosis and refractory ascites. However, other evidence implies that NSBB may be beneficial in this setting by reducing bacterial translocation. Our aim was to determine whether NSBB use was a risk factor for mortality in patients with end-stage chronic liver disease and ascites awaiting liver transplantation.
3329. A phase II study of laquinimod in Crohn's disease.
作者: Geert D'Haens.;William J Sandborn.;Jean Frederic Colombel.;Paul Rutgeerts.;Kurt Brown.;Hadas Barkay.;Anat Sakov.;Asi Haviv.;Brian G Feagan.; .
来源: Gut. 2015年64卷8期1227-35页
Laquinimod is an oral therapeutic agent under investigation for the treatment of Crohn's disease (CD), Huntington's disease, lupus nephritis and multiple sclerosis. This dose escalation study evaluated the safety and efficacy of laquinimod as induction therapy in patients with active moderate-severe CD.
3331. Polymorphisms at PRSS1-PRSS2 and CLDN2-MORC4 loci associate with alcoholic and non-alcoholic chronic pancreatitis in a European replication study.
作者: Monique H Derikx.;Peter Kovacs.;Markus Scholz.;Emmanuelle Masson.;Jian-Min Chen.;Claudia Ruffert.;Peter Lichtner.;Rene H M Te Morsche.;Giulia Martina Cavestro.;Claude Férec.;Joost P H Drenth.;Heiko Witt.;Jonas Rosendahl.; .
来源: Gut. 2015年64卷9期1426-33页
Several genetic risk factors have been identified for non-alcoholic chronic pancreatitis (NACP). A genome-wide association study reported an association of chronic pancreatitis (CP) with variants in PRSS1-PRSS2 (rs10273639; near the gene encoding cationic trypsinogen) and CLDN2-MORC4 loci (rs7057398 in RIPPLY1 and rs12688220 in MORC4). We aimed to refine these findings in a large European cohort.
3332. The ATG16L1-T300A allele impairs clearance of pathosymbionts in the inflamed ileal mucosa of Crohn's disease patients.
作者: Mehdi Sadaghian Sadabad.;Anouk Regeling.;Marcus C de Goffau.;Tjasso Blokzijl.;Rinse K Weersma.;John Penders.;Klaas Nico Faber.;Hermie J M Harmsen.;Gerard Dijkstra.
来源: Gut. 2015年64卷10期1546-52页
Crohn's disease (CD) is caused by a complex interplay among genetic, microbial and environmental factors. ATG16L1 is an important genetic factor involved in innate immunity, including autophagy and phagocytosis of microbial components from the gut. We investigated the effect of inflammation on the composition of microbiota in the ileal mucosa of CD patients in relation to the ATG16L1 risk status.
3333. Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts.
作者: Weronica E Ek.;Anna Reznichenko.;Stephan Ripke.;Beate Niesler.;Marco Zucchelli.;Natalia V Rivera.;Peter T Schmidt.;Nancy L Pedersen.;Patrik Magnusson.;Nicholas J Talley.;Elizabeth G Holliday.;Lesley Houghton.;Maria Gazouli.;George Karamanolis.;Gudrun Rappold.;Barbara Burwinkel.;Harald Surowy.;Joseph Rafter.;Ghazaleh Assadi.;Ling Li.;Evangelia Papadaki.;Dario Gambaccini.;Santino Marchi.;Rocchina Colucci.;Corrado Blandizzi.;Raffaella Barbaro.;Pontus Karling.;Susanna Walter.;Bodil Ohlsson.;Hans Tornblom.;Francesca Bresso.;Anna Andreasson.;Aldona Dlugosz.;Magnus Simren.;Lars Agreus.;Greger Lindberg.;Guy Boeckxstaens.;Massimo Bellini.;Vincenzo Stanghellini.;Giovanni Barbara.;Mark J Daly.;Michael Camilleri.;Mira M Wouters.;Mauro D'Amato.
来源: Gut. 2015年64卷11期1774-82页
IBS shows genetic predisposition, but adequately powered gene-hunting efforts have been scarce so far. We sought to identify true IBS genetic risk factors by means of genome-wide association (GWA) and independent replication studies.
3334. Comparing histological activity indexes in UC.
作者: Aude Bressenot.;Julia Salleron.;Claire Bastien.;Silvio Danese.;Camille Boulagnon-Rombi.;Laurent Peyrin-Biroulet.
来源: Gut. 2015年64卷9期1412-8页
Assessment of disease activity in UC is important for designing an optimal therapeutic strategy. No single histology score is considered optimum. The aim of this study was to compare intraobserver reproducibility and the interobserver agreement of available histological UC activity indexes.
3335. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.
作者: Peiwei Li.;Han Wu.;Honghe Zhang.;Yu Shi.;Jinming Xu.;Yao Ye.;Dajing Xia.;Jun Yang.;Jianting Cai.;Yihua Wu.
来源: Gut. 2015年64卷9期1419-25页
The objective of this meta-analysis was to systematically assess the survival benefit of aspirin use before or after diagnosis for patients with colorectal cancer (CRC).
3336. Predictors and risks for death in a population-based study of persons with IBD in Manitoba.
作者: Charles N Bernstein.;Zoann Nugent.;Laura E Targownik.;Harminder Singh.;Lisa M Lix.
来源: Gut. 2015年64卷9期1403-11页
We aimed to determine the predictors and risk for death among persons with either Crohn's disease (CD) or UC compared with the general population.
3337. Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy).
作者: Manuel Zorzi.;Carlo Senore.;Filippo Da Re.;Alessandra Barca.;Luigina Ada Bonelli.;Renato Cannizzaro.;Renato Fasoli.;Lucia Di Furia.;Emilio Di Giulio.;Paola Mantellini.;Carlo Naldoni.;Romano Sassatelli.;Douglas Rex.;Cesare Hassan.;Marco Zappa.; .
来源: Gut. 2015年64卷9期1389-96页
To assess variation in the main colonoscopy quality indicators in organised colorectal cancer (CRC) screening programmes based on faecal immunochemical test (FIT).
3338. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific.
作者: Siew C Ng.;Whitney Tang.;Rupert W Leong.;Minhu Chen.;Yanna Ko.;Corrie Studd.;Ola Niewiadomski.;Sally Bell.;Michael A Kamm.;H J de Silva.;Anuradhani Kasturiratne.;Yasith Udara Senanayake.;Choon Jin Ooi.;Khoon-Lin Ling.;David Ong.;Khean Lee Goh.;Ida Hilmi.;Qin Ouyang.;Yu-Fang Wang.;PinJin Hu.;Zhenhua Zhu.;Zhirong Zeng.;Kaichun Wu.;Xin Wang.;Bing Xia.;Jin Li.;Pises Pisespongsa.;Sathaporn Manatsathit.;Satimai Aniwan.;Marcellus Simadibrata.;Murdani Abdullah.;Steve W C Tsang.;Tai Chiu Wong.;Aric J Hui.;Chung Mo Chow.;Hon Ho Yu.;Mo Fong Li.;Ka Kei Ng.;Jessica Ching.;Justin C Y Wu.;Francis K L Chan.;Joseph J Y Sung.; .
来源: Gut. 2015年64卷7期1063-71页
The rising incidence of inflammatory bowel disease in Asia supports the importance of environmental risk factors in disease aetiology. This prospective population-based case-control study in Asia-Pacific examined risk factors prior to patients developing IBD.
3339. Impact of common risk factors of fibrosis progression in chronic hepatitis C.
作者: S Rüeger.;P-Y Bochud.;J-F Dufour.;B Müllhaupt.;D Semela.;M H Heim.;D Moradpour.;A Cerny.;R Malinverni.;D R Booth.;V Suppiah.;J George.;L Argiro.;P Halfon.;M Bourlière.;A H Talal.;I M Jacobson.;E Patin.;B Nalpas.;T Poynard.;S Pol.;L Abel.;Z Kutalik.;F Negro.
来源: Gut. 2015年64卷10期1605-15页
The natural course of chronic hepatitis C varies widely. To improve the profiling of patients at risk of developing advanced liver disease, we assessed the relative contribution of factors for liver fibrosis progression in hepatitis C.
3340. Prevalence of small-bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy.
作者: Jasmijn F Haanstra.;Abdul Al-Toma.;Evelien Dekker.;Steven A L W Vanhoutvin.;Fokko M Nagengast.;Elisabeth M Mathus-Vliegen.;Monique E van Leerdam.;Wouter H de Vos tot Nederveen Cappel.;Silvia Sanduleanu.;Roeland A Veenendaal.;Annemieke Cats.;Hans F A Vasen.;Jan H Kleibeuker.;Jan J Koornstra.
来源: Gut. 2015年64卷10期1578-83页
The aim was to determine the prevalence of small-bowel neoplasia in asymptomatic patients with Lynch syndrome (LS) by video capsule endoscopy (VCE).
|